Advances in Neurofibromatosis: Integrating Multi-modality Therapy

Live Virtual CME Experience
Friday, October 9, 2020 (8:45 am-4:15 pm)

NF Flyer

This live virtual conference is intended to provide an update on current evaluation and multi-modality therapy for neurofibromatosis.

Neurofibromatosis represents a group of inheritable disorders that require multi-disciplinary integrated care. Major advances in defining molecular alterations and developing targeted therapies have changed the landscape of treatment, but require continued laboratory and clinical investigations. Clinicians and scientists at Memorial Sloan Kettering Cancer Center (MSK) are pursuing numerous areas of investigation in the clinic and laboratory and we anticipate will become one of the driving forces in the development of newer therapies for both benign and malignant tumors (eg MPNST) in NF-associated tumors. Additionally, MSK is one of the most active surgical groups in the world with the recent integration of advanced technologies such as DaVinci robot resection of paraspinal benign tumors.


Register online now
NF1/MPNST Sessions
Genetics of NF1
Imaging of NF1
NF1 Targeted Therapy
Preclinical Models NF1
Clinical Trials for MPNST
Surgerical Management for MPNST
NF1-associated Tumors (GIST, Breast)
Management of Long Bone Dysplasias
Tumor Board
NF2/Schwannomatosis Sessions
Genetics of NF2/Schwannomatosis
Imaging of NF2/Schwannomatosis
Molecular Targeted Therapies for NF2
Surgical Management of Vestibular Schwannomas
Schwannomatosis: Robotic Resection
The Role of Radiation Therapy in NF
Pain Management
Tumor Board
A complete faculty list and agenda will be available online soon:

Join the conversation with @MSKCME using the course hashtag: #MSKneurofibCME